Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program

Research output: Contribution to journalArticle

Abstract

Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the "valley of death." The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316-318.

Original languageEnglish (US)
Pages (from-to)316-318
Number of pages3
JournalClinical and Translational Science
Volume3
Issue number6
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Translational Medical Research
Research
Intellectual Property
Equipment and Supplies
Financial Management
Intellectual property
Research Personnel
Pharmaceutical Preparations
Industry

Keywords

  • Medical school administration
  • Pilot programs
  • Translational continuum
  • University-foundation partnerships
  • Valley of death

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{ae36054ad81d495c9d76267ae2e4cd9a,
title = "Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program",
abstract = "Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the {"}valley of death.{"} The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316-318.",
keywords = "Medical school administration, Pilot programs, Translational continuum, University-foundation partnerships, Valley of death",
author = "Kenneth Pienta",
year = "2010",
month = "12",
doi = "10.1111/j.1752-8062.2010.00248.x",
language = "English (US)",
volume = "3",
pages = "316--318",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Successfully Accelerating Translational Research at an Academic Medical Center

T2 - The University of Michigan-Coulter Translational Research Partnership Program

AU - Pienta, Kenneth

PY - 2010/12

Y1 - 2010/12

N2 - Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the "valley of death." The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316-318.

AB - Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the "valley of death." The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316-318.

KW - Medical school administration

KW - Pilot programs

KW - Translational continuum

KW - University-foundation partnerships

KW - Valley of death

UR - http://www.scopus.com/inward/record.url?scp=78650242496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650242496&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2010.00248.x

DO - 10.1111/j.1752-8062.2010.00248.x

M3 - Article

C2 - 21167009

AN - SCOPUS:78650242496

VL - 3

SP - 316

EP - 318

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 6

ER -